Nelly Salem MD, Presenter: Nothing to Disclose

Peter F. Faulhaber MD, Abstract Co-Author: Speaker, Koninklijke Philips NV Grant, Koninklijke Philips NV Medical Advisor, MIM Software Inc

Raymond Muzic PhD, Abstract Co-Author: Research Grant, Koninklijke Philips NV

Kuan-Hao Dylan Su, Abstract Co-Author: Nothing to Disclose

Donna M. Plecha MD, Abstract Co-Author: Advisory Board, Hologic, Inc Research Grant, SuperSonic Imagine

1. Utilization of an integrated PET-MRI system enables visualization of PET and MRI data with the patient in the same position. This allows direct comparison of PET and MRI images. 2. The MRI component allows for superior soft-tissue contrast. 3. The PET component provides information about tumor metabolic activity. 4. The high sensitivity of MRI coupled with high specificity of PET could provide accurate evaluation of extent of disease, staging and follow-up after treatment.  

Introduction: Imaging plays a vital role in staging breast cancer, the formulation of the appropriate treatment regimen, and assessing response to therapy. Purpose: The purpose of this study is to evaluate the role of PET-MRI in optimizing imaging evaluation of patients with breast cancer. Role of PET-MRI in Patients with Breast Cancer: By utilizing an integrated PET-MRI system, patients benefit from the soft-tissue contrast and information on vascularity provided by MRI in addition to the metabolic information yielded from PET. Conclusion: Our institution’s experience with PET-MRI in breast cancer patients yields promising results. The use of an integrated PET-MRI system opens the door to many interesting questions, guiding the direction of our future work.      

http://abstract.rsna.org/uploads/2014/14002496/14002496_tjx9.pdf

Salem, N, Faulhaber, P, Muzic, R, Su, K, Plecha, D, PET-MRI in Evaluation of Breast Cancer.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14002496.html